Patents by Inventor Alan Robert Saltiel

Alan Robert Saltiel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
    Patent number: 7169816
    Abstract: Phenylamino benzhydroxamic acid derivatives of the formula where R1, R2, R3, R4, R5, and R6 are hydrogen or substituent groups such as alkyl, and where R7 is hydrogen or an organic radical, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as psoriasis and restenosis.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: January 30, 2007
    Assignee: Warner-Lambert Company
    Inventors: Stephen Douglas Barrett, Alexander James Bridges, Annette Marian Doherty, David Thomas Dudley, Alan Robert Saltiel, Haile Tecle
  • 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives
    Patent number: 7019033
    Abstract: Phenylamino benzoic acid, benzamides, and benzyl alcohol derivatives of the formula where R1, R2, R3, R4, R5, and R6 are hydrogen or substituent groups such as alkyl, and where R7 is hydrogen or an organic radical, and Z is COOR7, tetrazolyl, CONR6R7, or CH2OR7, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as inflammation, psoriasis and restenosis, as well as stroke, heart failure, and immunodeficiency disorders.
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: March 28, 2006
    Assignee: Warner-Lambert Company
    Inventors: Stephen Douglas Barrett, Alexander James Bridges, Donna Reynolds Cody, Annette Marian Doherty, David Thomas Dudley, Alan Robert Saltiel, Mel Conrad Schroeder, Haile Tecle
  • 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
    Patent number: 6821963
    Abstract: Phenylamino benzhydroxamic acid derivatives of formula (I) where R1, R2, R3, R4, R5, and R6 are hydrogen or substituent groups such as alkyl, and where R7 is hydrogen or an organic radical, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as psoriasis and restenosis.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: November 23, 2004
    Assignee: Warner-Lambert Company
    Inventors: Stephen Douglas Barrett, Alexander James Bridges, Annette Marian Doherty, David Thomas Dudley, Alan Robert Saltiel, Haile Tecle
  • Treatment of asthma with MEK inhibitors
    Publication number: 20040141924
    Abstract: This invention provides a method of preventing or treating asthma by administering to a patient in need of treatment an effective amount of a selective MEK inhibitor, especially a phenyl amine of Formula I and II: 1
    Type: Application
    Filed: January 7, 2004
    Publication date: July 22, 2004
    Inventors: Alexander James Bridges, David Thomas Dudley, James Leslie Mobley, Alan Robert Saltiel
  • Treatment of asthma with MEK inhibitors
    Patent number: 6696440
    Abstract: This invention provides a method of preventing or treating asthma by administering to a patient in need of treatment an effective amount of a selective MEK inhibitor, especially a phenyl amine of Formula I and II:
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: February 24, 2004
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, David Thomas Dudley, James Leslie Mobley, Alan Robert Saltiel
  • 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives
    Publication number: 20030149015
    Abstract: Phenylamino benzoic acid, benzamides, and benzyl alcohol derivatives of the formula 1
    Type: Application
    Filed: December 10, 2002
    Publication date: August 7, 2003
    Inventors: Stephen Douglas Barrett, Alexander James Bridges, Donna Reynolds Cody, Annette Marian Doherty, David Thomas Dudley, Alan Robert Saltiel, Mel Conrad Schroeder, Haile Tecle
  • 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
    Publication number: 20030078428
    Abstract: Phenylamino benzhydroxamic acid derivatives of formula (I) where R1, R2, R3, R4, R5, and R6 are hydrogen or substituent groups such as alkyl, and where R7 is hydrogen or an organic radical, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as psoriasis and restenosis.
    Type: Application
    Filed: June 4, 2002
    Publication date: April 24, 2003
    Inventors: Stephen Douglas Barrett, Alexander James Bridges, Annette Marian Doherty, David Thomas Dudley, Alan Robert Saltiel, Haile Tecle
  • 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives
    Patent number: 6492363
    Abstract: Phenylamino benzoic acid, benzamides, and benzyl alcohol derivatives of the formula where R1, R2, R3, R4, R5, and R6 are hydrogen or substituent groups such as alkyl, and where R7 is hydrogen or an organic radical, and Z is COOR7, tetrazolyl, CONR6R7, or CH2OR7, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as inflammation, psoriasis and restenosis, as well as stroke, heart failure, and immunodeficiency disorders.
    Type: Grant
    Filed: August 16, 2001
    Date of Patent: December 10, 2002
    Assignee: Warner-Lambert Company
    Inventors: Stephen Douglas Barrett, Alexander James Bridges, Donna Reynolds Cody, Annette Marian Doherty, David Thomas Dudley, Alan Robert Saltiel, Mel Conrad Schroeder, Haile Tecle
  • 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives
    Publication number: 20020022647
    Abstract: Phenylamino benzoic acid, benzamides, and benzyl alcohol derivatives of the formula 1
    Type: Application
    Filed: August 16, 2001
    Publication date: February 21, 2002
    Inventors: Stephen Douglas Barrett, Alexander James Bridges, Donna Reynolds Cody, Annette Marian Doherty, David Thomas Dudley, Alan Robert Saltiel, Mel Conrad Schroeder, Haile Tecle
  • 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
    Patent number: 6310060
    Abstract: Phenylamino benzoic acid, benzamides, and benzyl alcohol derivatives of the formula where R1, R2, R3, R4, R5, and R6 are hydrogen or substituent groups such as alkyl, and where R7 is hydrogen or an organic radical, and Z is COOR7, tetrazolyl, CONR6R7, or CH2OR7, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as inflammation, psoriasis and restenosis, as well as stroke, heart failure, and immunodeficiency disorders.
    Type: Grant
    Filed: January 5, 2000
    Date of Patent: October 30, 2001
    Assignee: Warner-Lambert Company
    Inventors: Stephen Douglas Barrett, Alexander James Bridges, Donna Reynolds Cody, Annette Marian Doherty, David Thomas Dudley, Alan Robert Saltiel, Mel Conrad Schroeder, Haile Tecle
  • Method of treating or preventing septic shock by administering a MEK inhibitor
    Patent number: 6251943
    Abstract: The present invention provides a method for treating or preventing septic shock. Specifically, the present invention provides a method of treating or preventing septic shock by administering to a patient a MEK inhibitor.
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: June 26, 2001
    Assignee: Warner-Lambert Company
    Inventors: Stephen Douglas Barrett, Alexander James Bridges, Donna Reynolds Cody, Annette Marian Doherty, David Thomas Dudley, Alan Robert Saltiel, Mel Conrad Schroeder, Haile Tecle
  • Protein targeting to glycogen
    Patent number: 6252057
    Abstract: The present invention provides human and murine genomic and complementary DNA and the proteins that are encoded by the DNA, which is called “Protein Targeting to Glycogen”. Also provided is a method of increasing the amount of glycogen in a cell.
    Type: Grant
    Filed: February 25, 1999
    Date of Patent: June 26, 2001
    Assignee: Warner-Lambert Company
    Inventors: Matthew Jemail Brady, John Andrew Printen, Alan Robert Saltiel
  • Carboxyalkylethers, formulations, and treatment of vascular diseases
    Patent number: 5783600
    Abstract: Dialkyl ethers lower Lp(a) and triglycerides, and elevate HDL-cholesterol, and are thereby useful for treating vascular diseases and noninsulin-dependent diabetes mellitus.
    Type: Grant
    Filed: February 25, 1997
    Date of Patent: July 21, 1998
    Assignee: Warner-Lambert Company
    Inventors: Charles Larry Bisgaier, Paul Leroy Creger, Alan Robert Saltiel, Sherrie Rae Tafuri
  • Carboxyalkylethers, formulations, and treatment of vascular diseases
    Patent number: 5756544
    Abstract: Dialkyl ethers lower Lp(a) and triglycerides, and elevate HDL-cholesterol, and are thereby useful for treating vascular diseases and noninsulin-dependent diabetes mellitus.
    Type: Grant
    Filed: February 25, 1997
    Date of Patent: May 26, 1998
    Assignee: Warner-Lambert Company
    Inventors: Charles Larry Bisgaier, Paul Leroy Creger, Alan Robert Saltiel, Sherrie Rae Tafuri
  • Carboxyalkylethers, formulations, and treatment of vascular diseases
    Patent number: 5750569
    Abstract: Dialkyl ethers lower Lp(a) and triglycerides, and elevate HDL-cholesterol, and are thereby useful for treating vascular diseases and noninsulin-dependent diabetes mellitus.
    Type: Grant
    Filed: February 25, 1997
    Date of Patent: May 12, 1998
    Assignee: Warner-Lambert Company
    Inventors: Charles Larry Bisgaier, Paul Leroy Creger, Alan Robert Saltiel, Sherrie Rae Tafuri
  • Substituted imidazolinyl-imidazolines as antagonists of SH-2 binding and therapeutic uses thereof
    Patent number: 5721266
    Abstract: Methods of treating proliferative diseases or viral, inflammatory, allergic and cardiovascular diseases, and restenosis are disclosed. The present invention demonstrates the use of N,N'-piperazinylbis-?2-amino-1-imidazolin-2-yl)-2-imidazolines!, 2-amino-1-(2-imidazolin-2-yl)-2-imidazolines, and N,N'-alkylene-bis?2-amino-1-(2-imidazolin-2-yl)-2-imidazolines!, their derivatives, and salts thereof, to antagonize the association of a protein tyrosine kinase with a substrate regulatory protein. The present invention also demonstrates the use of pharmaceutical compositions employing N,N'-piperazinylbis?2-amino-1-imidazolin-2-yl)-2-imidazolines!, 2-amino-1-(2-imidazolin-2-yl)-2-imidazolines, and N,N'-alkylenebis-?2-amino-1-(2-imidazolin-2-yl)-2-imidazolines!, their derivatives, and salts thereof, to antagonize the association of a protein tyrosine kinase with substrate regulatory protein. The present invention also relates to novel N,N'-piperazinylbis?2-amino-1-imidazolin-2-yl)-2-imidazolines!.
    Type: Grant
    Filed: September 26, 1994
    Date of Patent: February 24, 1998
    Assignee: Warner-Lambert Company
    Inventors: Stuart James Decker, David William Fry, James Marino Hamby, Alan Robert Saltiel
  • Carboxyalkylethers, formulations, and treatment of vascular diseases
    Patent number: 5648387
    Abstract: Dialkyl ethers lower Lp(a) and triglycerides, and elevate HDL-cholesterol, and are thereby useful for treating vascular diseases and noninsulin-dependent diabetes mellitus.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: July 15, 1997
    Assignee: Warner-Lambert Company
    Inventors: Charles Larry Bisgaier, Paul Leroy Creger, Alan Robert Saltiel, Sherrie Rae Tafuri